Aim. To present basic data on botulinum toxin type A (BTX-A) in the treatment of cerebral palsy.
Review. BTX-A is nowadays a widely used treatment for spasticity due to cerebral palsy (CP). It is a registered therapy in the majority of European countries and Australia. Before the year 2001 156 studies were published on its usefulness and safety in CP. Nevertheless, there are only few studies regarding the short and long-term functional gains following BTX-A therapy. Recently published data suggest that BTX-A may trigger and produce a better functional outcome in CP patients, despite its transitory effect on muscle lone or passive range of motions. BTX-A seems to be especially useful in younger children (2-6 years old) with mild/moderate focal spasticity, without fixed contractures.